Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Protectin D1 Prevents Bird Flu Infection in Mouse Model

By BiotechDaily International staff writers
Posted on 21 Mar 2013
The omega-3 polyunsaturated fatty acid (PUFA)-derived lipid mediator glycoprotein protectin D1 (PD1) prevents infection by the influenza virus, including the deadly H5N1 strain of bird flu, in a mouse model.

Around 60% of humans known to have been infected with the current Asian strain of bird flu (H5N1) have died from it, and virologists fear that H5N1 may mutate or undergo an antigenic shift into a strain capable of efficient human-to-human transmission.

PD1, which is also known as CD59 complement regulatory protein, is a cell surface glycoprotein that regulates complement-mediated cell lysis and is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. Viruses such as HIV, human cytomegalovirus, and vaccinia incorporate host cell PD1 into their own viral envelope to prevent lysis by complement. PD1 also plays a role in signal transduction pathways in the activation of T-cells.

Investigators at Akita University (Japan) screened compounds for their ability to inhibit influenza virus replication in human lung tissue. The most active compound they found was PD1. Results published in the March 7, 2013, online edition of the journal Cell revealed that PD1 markedly lessened influenza virus replication via RNA export machinery. Production of PD1 was suppressed during severe influenza, and PD1 levels inversely correlated with the pathogenicity of H5N1 viruses. PD1 treatment improved the survival and pathology of mice with severe influenza infection, even under conditions where known antiviral drugs failed to protect from death.

"Given the potential for future lethal pandemics, effective drugs are needed for the treatment of severe influenza, such as that caused by H5N1 viruses," said senior author Dr. Yumiko Imai, professor of experimental medicine at Akita University. "We have identified a novel therapeutic target for the treatment of severe influenza that is effective under conditions where known antiviral drugs fail to protect from death. Our findings suggest that PD1could serve as a biomarker as well as a much needed antiviral drug for severe and lethal influenza virus infections."

Related Links:

Akita University




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.